Asthma diagnosis and treatmentAsthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists
Section snippets
ACT survey
The ACT survey is a patient-completed questionnaire with 5 items assessing asthma symptoms (daytime and nocturnal), use of rescue medications, and the effect of asthma on daily functioning (Fig 1). Each item includes 5 response options corresponding to a 5-point Likert-type rating scale. In scoring the ACT survey, responses for each of the 5 items are summed to yield a score ranging from 5 (poor control of asthma) to 25 (complete control of asthma). Details of the development of the ACT are
Sample
The number of patients participating in the study was 313. The mean age of the patients was 35 years (SD, 15.3), with a range of 12 to 84 years. At the baseline visit, specialists rated asthma control as well controlled or completely controlled in 48% of the 301 patients for whom data were available, somewhat controlled in 29% of the patients, and poorly controlled or not controlled at all in 23% of patients. The mean percent predicted FEV1 value at the baseline visit for the 301 patients for
Discussion
A cornerstone of the NAEPP guidelines for managing asthma is the ongoing assessment of asthma control, which is crucial for optimizing care and reducing the humanistic, economic, and societal burdens of the disease. Data suggest that patients with asthma and their physicians often overestimate the degree to which asthma is controlled.12 Overestimation of asthma control can result in failure to use needed interventions or to make necessary adjustments to medication regimens; the lack of
References (22)
- et al.
The health economics of asthma and rhinitis. I. Assessing the economic impact
J Allergy Clin Immunol
(2001) - et al.
Asthma care practices, perceptions, and beliefs of Chicago-area asthma specialists. Chicago Asthma Surveillance Initiative Project Team
Chest
(1999) Assessment of asthma control and severity
Ann Allergy Asthma Immunol
(2004)- et al.
Determinants of different dimensions of disease severity in asthma and COPD: pulmonary function and health-related quality of life
Chest
(2001) - et al.
Predicting children's quality of life in an asthma clinical trial: what do children's reports tell us?
J Pediatr
(2001) - et al.
A scale for the measurement of quality of life in adults with asthma
J Clin Epidemiol
(1992) - et al.
Development of the Asthma Control Test: a survey for assessing asthma control
J Allergy Clin Immunol
(2004) - et al.
Measurement properties and interpretation of three shortened versions of the asthma control questionnaire
Respir Med
(2005) - Trends in Asthma Morbidity and Mortality 2005. American Lung Association Epidemiology & Statistics Unit Research and...
Asthma prevalence and control characteristics by race/ethnicity—United States, 2002
MMWR Morb Mortal Wkly Rep
(2004)
Asthma in the United States: recent trends and current status
J Manag Care Pharm
Cited by (0)
The research described in this article was funded by GlaxoSmithKline.
Disclosure of potential conflict of interest: M. Schatz has received grants–research support from GlaxoSmithKline and Sanofi-Aventis and is on the speakers' bureau for AstraZeneca and Merck. C. A. Sorkness has consultant arrangements with GlaxoSmithKline and AstraZeneca, has received grants–research support from GlaxoSmithKline, and is on the speakers' bureau for GlaxoSmithKline and Genentech. J. T. Li has had consultant arrangements with GlaxoSmithKline and has received grants–research support from GlaxoSmithKline. P. Marcus has consultant arrangements with Altana, has received grants–research support from GlaxoSmithKline and AstraZeneca, and is on the speakers' bureau for GlaxoSmithKline, Genentech, Novarits, Merck, and Aventis. J. J. Murray has consultant arrangements with GlaxoSmithKline, has received grants–research support from GlaxoSmithKline, and is on the speakers' bureau for GlaxoSmithKline. R. A. Nathan has consultant arrangements with Amgen, Altana, AstraZeneca, Aventis, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering/Key, Sepracor, and Viropharm; has received grants–research support from Abbot, Altana, Aventis, AstraZeneca, Bayer, Berlex, Boehringer Ingelheim, Bristol-Myers Squibb, Ciba-Geigy, Dura, Forest, GlaxoSmithKline, Immunex, Janssen, Parke-Davis, Pfizer, 3-M Pharmaceuticals, Proctor & Gamble, Roberts, Sandoz, Sanofi, Schering/Key, Sepracor, Sterling, Tap Pharmaceuticals, Wallace, and Wyeth; and is on the speakers' bureau for AstraZeneca, Aventis, Genentech/Novartis, GlaxoSmithKline, Pfizer, and Schering/Key. M. Kosinski—none declared. T. B. Pendergraft is employed by GlaxoSmithKline. P. Jhingran has stock or other equity ownership in and is employed by GlaxoSmithKline.